4th May 2010 12:05
For immediate release |
4 May 2010 |
ABCAM PLC
("Abcam" or "the Company")
Total Voting Rights - Voting Rights and Capital
In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: The Company's issued share capital consists of 35,949,871 Ordinary Shares of 1p each with voting rights. The Company does not hold any shares in Treasury. The above figure of 35,949,871 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
Date of Notification: 4 May 2010
For further information please contact:
Abcam |
+ 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer |
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser |
|
James Black - Corporate Broking |
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
Mark Court / Stasa Filiplic |
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
Related Shares:
ABC.L